The Burden of Familia Chylomicronemia Syndrome in Canadian Patients

Home / Intelligence / Scientific Publications / The Burden of Familia Chylomicronemia Syndrome in Canadian Patients

Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder characterized by persistent extreme hypertriglyceridemia as a result of lipoprotein lipase deficiency. Canada is an important region for FCS research due to the high prevalence rates. The burden of illness and quality of life of Canadian patients, however, have been inadequately addressed in the literature. The objective of this study is to understand the burden of illness of FCS on Canadian patients’ lives.

Authors

Daniel Gaudet, Michael Stevenson, Nelly Komari, Grace Trentin, Caroline Crowson, Nandini Hadker, Sophie Bernard

Journal

Lipids in Health and Disease

View publication

Related Intelligence

Scientific Publications

ISPOR EU 2024 Research Posters

RWD8 Maximizing the Value of Real-World Data in HEOR – a Comparative Assessment of Claims and Emr Sources in Europe Authors: Diehl M, Saikumar S, Furrer DE, Kulkarni A, Patel N, Hadker N Abstract: OBJECTIVES: Heterogeneity in the European RWD landscape, both regionally and across vendors, requires fit-for-purpose dataset selection in HEOR studies. Visibility into […]

Scientific Publications

ISPOR US 2024 Research Posters

Healthcare Resource Utilization of Patients with Short Bowel Syndrome Dependent on Parenteral Support: A Retrospective Claims Analysis AUTHOR(S): Ali A1, Micic D2, Gallivan M1, Kulkarni A3, Henderson J4, Mitchell G4 1Trinity Life Sciences, Waltham, MA, USA, 2University of Chicago Medical Center, Gastroenterology, Hepatology, and Nutrition, Chicago, IL, USA, 3Trinity Life Sciences, Malden, MA, USA, 4VectivBio AG, Basel, Basel, Switzerland […]

Scientific Publications

ISPOR EU 2023 Research Posters

Implications of the Implementation of the Joint Committee Assessment on Launch Planning for Medical Technologies in Europe Acosta Luis S1, O’Hara M2, Yeh M2 1Trinity Partners, LLC, London, UK, 2Trinity Life Sciences, Waltham, MA, USA The EU-wide Joint Clinical Assessment (JCA) is set to be operational from January 2025. The Trinity team reviewed the available literature […]